VivoSeq
Other

Granuloma

28

Pipeline Programs↗

7

Active Trials↗

14

Companies Involved↗

Granuloma is an emerging landscape with 28 programs across 14 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Eli Lilly, AstraZeneca. 5 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

11/100

Mech. Concentration

18/100

Completion Rate

85/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical4

Triple Anti-Tuberculosis Drug

First Affiliated Hospital of Harbin Medical University

Sclerotherapy

University of Minnesota

Corticosteroid Therapy

Sanofi

Doxycyclin

Tanta University

Phase 13

Rituximab

Roche

Mycophenolate Mofetil

Roche

Interleukin-10

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 214

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Baricitinib

Eli Lilly

Fasenra

AstraZeneca

Omeprazole

Dexcel Pharma Technologies Ltd.

Cyclophosphamide

Baxter Healthcare Corporation

Phase 32

Esomeprazole

Dexcel Pharma Technologies Ltd.

Etanercept

Immunex

Approved5

Methylprednisolone

Pfizer

Prednisone

Roxane Laboratories

Betadine

Egymedicalpedia

Compound Betamethasone

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Hydrocortisone Butyrate

European Organisation for Research and Treatment of Cancer - EORTC

Analysis

Modality Breakdown

85%

Small molecule

28 of 33 classified programs — the dominant modality here.

15%ALL OTHERSProtein / enzyme39%Monoclonal antibody26%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 36 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed17 · 59%
Recruiting3 · 10%
Not yet recruiting3 · 10%
Unknown status2 · 7%
Withdrawn2 · 7%
Active, not recruiting1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

29 trials

Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis
Recruiting·FFirst Affiliated Hospital of Harbin Medical University·N/A·NCT06565845·350 enrolled
Cohort of Patients With Systemic Granulomatosis and Associated Biological Collection
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT06854848·150 enrolled
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001405·850 enrolled
Baricitinib in Idiopathic Granulomatous Mastitis
Active, not recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT05852171·20 enrolled
Effect of Laser and Sclerotic Agent in the Treatment of Oral Granuloma
Not yet recruiting·—·N/A·NCT06639230·20 enrolled
Steroid Injection in Idiopathic Granulomatous Mastitis
Not yet recruiting·—·Phase 1·NCT06985537·40 enrolled
Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis
Not yet recruiting·—·Phase 1/2·NCT07454772·72 enrolled
Treatment of Wegener's Granulomatosis With Cyclophosphamide
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001155·200 enrolled
Treatment of Granuloma Umbilical in Newborn Babies
Completed·—·Phase 2·NCT01567215·90 enrolled
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00072592·10 enrolled
Treatment of Tracheostomy Granulomas
Completed·UUniversity of Colorado, Denver·Phase 4·NCT02116608·26 enrolled
Ductal Lavage Versus Corticosteroids Therapy for Idiopathic Granulomatous Mastitis
Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT03724903·140 enrolled
Etanercept to Treat Wegener's Granulomatosis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001901·60 enrolled
Daclizumab to Treat Wegener's Granulomatosis
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00040248·75 enrolled
Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma
Completed·SShiraz University of Medical Sciences·Phase 2·NCT02358304·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)